Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMWH versus unfractionated heparin in NSTEMI with end-stage kidney disease
TCTR20250818018Unknown
- Sponsor
- N/A
- Start
- Sep 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of low molecular weight heparin calcium and heparin in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) and end-stage kidney disease (ESKD) (2 arms), sponsored by N/A. Status: unknown.
02
Drugs
low molecular weight heparin calciumheparin
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on TCTR20250818018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250818018.